Chugai Pharmaceutical Obtains Approval for Covid Antibody Cocktail
July 19 2021 - 9:58PM
Dow Jones News
By Kosaku Narioka
Chugai Pharmaceutical Co. obtained regulatory approval in Japan
for a Covid-19 antibody cocktail created by Regeneron
Pharmaceuticals Inc.
The Japanese unit of Swiss drug maker Roche Holding AG said
Monday that the antibody cocktail, Ronapreve, was approved to treat
mild to moderate Covid-19 patients.
Regeneron and Roche agreed to jointly manufacture, develop and
distribute the antibody cocktail.
Chugai said it had reached an agreement with the Japanese
government to secure domestic supply of the antibody cocktail for
2021.
Chugai said Ronapreve hasn't yet been approved in countries
other than Japan.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
July 19, 2021 21:51 ET (01:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
